Erasca reports early PRs for ERAS-0015 at 8 mg QD; Phase 1 dose escalation faster than expected

Erasca, Inc.

ERAS-0015 AURORAS-1 trial: two confirmed PRs and one unconfirmed PR in patients with different tumor types and RAS mutations at 8 mg QD.
No dose-limiting toxicities; predominantly low-grade AEs; linear PK across all dose levels evaluated (data cutoff Jan 7, 2026).
Initial Phase 1 monotherapy data for ERAS-0015 planned for H1 2026; expansion/combination cohorts start H2 2026.
ERAS-4001 BOREALIS-1 Phase 1 dose escalation advancing as expected; initial monotherapy data planned H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.